Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout

by NASDAQ Market News November 11, 2019

NASDAQ Market News
Click here to email author

Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast

Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV

Ads